Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, TRI, FVT

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science



ORCHARD PARK, N.Y., Dec. 7, 2017 /PRNewswire/ -- Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.

"We're dedicated to the wide dissemination of scientific advances to improve understanding and spur future discoveries," said Mikhail Blagosklonny, Oncotarget's editor-in-chief. "The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting."

The sponsored researchers presented studies ranging from assessing the impact of drug treatments on kidney cancer to characterizing the chemoresistance of asbestos-related tumors.  The researchers and their presentations are as follows:

The FCS 2017 conference, which was held November 6 ? 8th, was hosted by seven major research institutes: Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology and Lee Kong Chian School of Medicine.

For more biomedical research in oncology and related areas such as immunology and microbiology, the latest issue of Oncotarget is available at http://www.impactjournals.com/oncotarget.

About Oncotarget

Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact Information:

Ryan James Jessup
Rapamycin Press
202-638-9720
RyanJamesJessup@RapamycinPress.com

 

SOURCE Oncotarget


These press releases may also interest you

at 02:17
Cogobuy Group ("Cogobuy" or the "Company", stock code: 400.HK), an e-commerce platform serving the electronics manufacturing industry in China, announces that the Company has gradually overcome the impact of its tightened credit facilities. Its...

16 déc 2017
The U.S. Navy commissioned USS Little Rock (LCS 9) ?? the nation's fifth Freedom-variant Littoral Combat Ship (LCS) ?? on the Buffalo River on Dec. 16. This milestone officially places the ship, which was designed and built by Lockheed Martin and...

16 déc 2017
Candor, a technology and marketplace company specializing in pairing consumers with top health plans, announces the acquisition of Tenex, a comprehensive software development company. Candor is strengthened by the transaction and now has the ability...

16 déc 2017
Lowcarinsurancequotes.info has released a new blog post explaining how to analyze auto insurance offers with online quotes. Clients can now get car insurance quotes on a single website, without having to spend time or money. Searching for the best...

16 déc 2017
Thierry Ehrmann, founder and CEO of Artprice: "The FCC's decision last night represents the most positive and significant event over the last 20 years of Artprice's history and it confirms beyond any doubt Artprice's revenue forecasts for the...

16 déc 2017
On Wednesday, Text IQ was named to the prestigious AI 100 list alongside just four other companies in the "Risk & Regulatory Compliance" category. Officially billed as "a ranking of the 100 most promising private artificial intelligence companies in...




News published on 7 december 2017 at 14:36 and distributed by: